SAN DIEGO, Aug. 02, 2019 (GLOBE NEWSWIRE) — Obalon Therapeutics Inc. (Nasdaq: OBLN) (the ?Company?), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced the pricing of an underwritten public offering of (i) 2,015,000 shares of common stock together with common stock warrants (the ?common warrants?) to purchase 1,511,250 shares of common stock and (ii) 1,735,000 pre-funded warrants, with each pre-funded warrant exercisable for one share of common stock, together with common warrants to purchase 1,301,250 shares of common stock. The shares of common stock (or pre-funded warrants, as applicable) and accompanying common warrants are being sold together at a combined public offering price of $4.00 per share. The pre-funded warrants are immediately exercisable and may be exercised at any time until all of the pre-funded w
